Endpoints News – Biotech and pharma business news, with a focus …
Endpoints News provides up-to-date biotech, drug, pharma, and health news for business and professional readers.
Special report 2024: Meet 20 women breaking new ground in …
Oct 7, 2024 · Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie …
Developing your new medicine in Japan faster
Nov 14, 2024 · Getting new medicines developed in Japan is now easier, thanks to regulatory streamlining and changes in the pricing system. Senior Japanese government officials and …
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather …
Big dreams dominate among next-gen biotech players
Sep 22, 2024 · Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks …
News – Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
Viking’s oral weight loss drug shows promising Phase 1 data
Nov 3, 2024 · SAN ANTONIO — Viking Therapeutics' highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks, sticking the …
Elucida Oncology shutters due to ‘lack of funding’
Oct 25, 2024 · Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has learned. The New Jersey startup was trying to …
Endpoints at #ASCO24
Jun 4, 2024 · Each year, the oncology world looks to the ASCO meeting to make sense of the clinical cancer landscape. Data coming out of the meeting will signal pipeline strengths and …
FDA delays decision on Amgen’s Lumakras in colorectal cancer
Oct 17, 2024 · The FDA has pushed back its decision deadline to move Amgen’s KRAS inhibitor Lumakras into metastatic colorectal cancer to January, the company told Endpoints News. The …
Skip to content